GLP1 + GIP 10mg

INTENDED FOR RESEARCH PURPOSES! All of the above-mentioned properties are observed in laboratory studies, not performed on humans, and are for informational purposes only. None of the information contained in the descriptions has been approved by GIS, GIF, or EFSA. The substance is not a medicine, food product, or dietary supplement, and consequently it is not suitable for human consumption.

The product qualifies as a chemical reagent / reference material approved for sale within the EU. It may be used solely for scientific research. Additional information about the agent is contained in the safety data sheet of the chemical substance, which we make available for inspection. The products are available only to institutions or private individuals associated with research or laboratory activity.

GLP-1 + GIP is a chemical reagent containing a synthetically produced combination of amino acid sequences corresponding to the active forms of the peptides GLP-1 and GIP. The preparation is available as a lyophilized powder with 10 mg of active substance, intended for reconstitution in an appropriate solvent before use in in vitro research procedures.

In the Pro-Body offer other variants of this peptide are also available: GLP-1 + GIP 5 mg, GLP-1 + GIP 10 mg and GLP-1 + GIP PEN 10 mg.

GLP-1 in its active form (GLP-1(7-36)amide or GLP-1(7-37)) is a peptide consisting of 30-31 amino acids. It is secreted in the process of post-translational processing of proglucagon by the prohormone convertase PC1/3 in the L cells of the small intestine and colon. The native form of GLP-1 is characterized by a very short plasma half-life (approximately 1.5-2 minutes), because it undergoes rapid degradation by the enzyme dipeptidyl peptidase IV (DPP-IV), which cleaves off two N-terminal amino acids.

GIP (glucose-dependent insulinotropic polypeptide) is a peptide composed of 42 amino acids, secreted by the K cells of the duodenum and jejunum. Like GLP-1, it is subject to degradation by DPP-IV, which results in a biological half-life of approximately 5-7 minutes.

Synthetic GLP-1 + GIP 10 mg may contain structural modifications intended to increase stability against enzymatic degradation under experimental conditions. Typical modifications include:

• Substitution of the amino acid alanine at position 2 (the DPP-IV cleavage site)
• Acylation with a fatty acid to increase affinity for plasma albumin
• C-terminal modifications affecting the conformation of the peptide

Peptides offered for research purposes by Pro-Body undergo rigorous quality control. Key analytical parameters include:

• HPLC purity – measured by high-performance liquid chromatography (HPLC) with UV detection. Expected purity ≥98%.
• Mass spectrometry (MS) – confirmation of peptide identity by analysis of molecular mass using ESI-MS or MALDI-TOF.
• Water content – determined by the Karl Fischer method, typically below 5% for the lyophilizate.
• Peptide content – determined by amino acid analysis (AAA) or based on UV absorption.
• Endotoxins – testing for the presence of bacterial endotoxins by the LAL (Limulus Amebocyte Lysate) method.

Each batch of the product should be accompanied by a Certificate of Analysis (CoA) containing the results of the above tests, the batch number, and the date of production.

Proper storage of the GLP-1 + GIP 10 mg peptide is of key importance for preserving its biological activity in in vitro experiments:

Lyophilized form (before reconstitution)

• Temperature: -20°C to -80°C (optimal long-term storage)
• Protect from moisture – store in tightly sealed containers with a desiccant
• Protect from direct exposure to light
• Stability in this form: up to 24 months from the date of production

Solution after reconstitution

• Reconstitution: use sterile bacteriostatic water or phosphate-buffered saline (PBS) at pH 7.4
• After dissolving, store at a temperature of 2-8°C for up to 14 days
• For long-term storage: divide into single-use portions (aliquots) and freeze at -20°C
• Avoid repeated freezing and thawing – each cycle reduces the activity of the peptide by 5-15%

Handling in the laboratory

• Work with the peptide should be carried out under aseptic conditions
• Use nitrile gloves and protective clothing
• Prepare solutions in a laminar flow cabinet (class II BSC)
• To measure out doses, use the peptide calculator

Under laboratory in vitro conditions, the mechanisms by which GLP-1 and GIP act on target cells have been studied in detail:

Activation of the GLP-1R receptor

GLP-1 binds to the GLP-1R receptor – a G protein-coupled receptor (GPCR) of class B1. After ligand binding, the Gαs protein is activated, which leads to an increase in the intracellular concentration of cAMP (cyclic adenosine monophosphate) through the activation of adenylyl cyclase. The increased concentration of cAMP activates protein kinase A (PKA) and the guanine nucleotide exchange factor Epac2 (Exchange protein directly activated by cAMP). In the β cells of the pancreatic islets (studied in vitro) this leads to:

• Closure of ATP-dependent potassium channels (KATP)
• Depolarization of the cell membrane
• Opening of voltage-dependent calcium channels
• Increase in the intracellular concentration of Ca²⁺ ions
• Exocytosis of granules containing insulin

Activation of the GIPR receptor

GIP acts on the GIPR receptor – also a receptor of the GPCR class B1 family. The signal transduction mechanism is analogous to GLP-1R and involves the cAMP/PKA pathway. However, GIPR exhibits a different tissue expression profile – in addition to the β cells of the pancreas, it also occurs in adipocytes (fat cells), osteoblasts, and neurons. In vitro studies on adipocytes have shown that activation of GIPR affects:

• Lipid metabolism in adipose tissue
• Stimulation of lipogenesis under conditions of hyperinsulinemia
• Modulation of the expression of genes associated with thermogenesis in brown adipose tissue

Synergy of GLP-1 and GIP in in vitro studies

Experiments on isolated islets of Langerhans and on cell lines (INS-1, MIN6) have shown that simultaneous activation of GLP-1R and GIPR leads to an additive or synergistic increase in insulin secretion compared with activation of each receptor separately. The mechanism of this synergy involves the convergence of cAMP pathways within the submembrane microdomain and the mutual modulation of receptor desensitization.

GLP-1 + GIP 10 mg finds application in many areas of biomedical research conducted under in vitro and in silico conditions:

Research on the biology of pancreatic islets

The peptide is used to study the mechanisms of insulin and glucagon secretion in isolated human and animal pancreatic islets. It allows the analysis of the effect of dual incretin stimulation on the kinetics of insulin secretion (the first and second phase of secretion) and on the survival of β cells under conditions of glucolipotoxicity.

Research on adipocyte metabolism

In primary adipocyte cultures and cell lines (3T3-L1), GLP-1 + GIP is used to study the effect on lipogenesis, lipolysis, and the expression of thermogenic genes (e.g., UCP-1 in brown adipose tissue). These studies help to understand the molecular basis of the effect of incretins on adipose tissue metabolism.

Neurobiological research

The GLP-1R and GIPR receptors are expressed in many areas of the brain, including the hypothalamus, hippocampus, and cerebral cortex. Studies on neuronal cultures (e.g., SH-SY5Y, primary hippocampal neurons) allow the analysis of the potential neuroprotective action of these peptides – in particular their effect on oxidative stress, apoptosis, and inflammatory processes within nervous tissue.

Research on insulin resistance

In in vitro models of insulin resistance (e.g., HepG2 hepatocytes treated with palmitate), GLP-1 + GIP is used to analyze its effect on the insulin signaling pathway (IRS-1/PI3K/Akt) and on the expression and activity of the GLUT4 glucose transporters.

Pharmaceutical screening

GLP-1 + GIP 10 mg serves as a reference substance in research on new analogs of incretin peptides. It allows the comparison of the strength of action (potency), receptor selectivity, and metabolic stability of new compounds in receptor-ligand binding assays and functional assays (cAMP measurement, insulin secretion).

GLP-1 + GIP 10 mg is a high-quality research peptide combining two key incretin sequences. It constitutes a valuable tool in the hands of scientists working in metabolic endocrinology, pancreatic islet biology, neurobiology, and pharmacology. Its application is limited solely to in vitro studies conducted under laboratory conditions. It is not a medicinal product, a dietary supplement, or a cosmetic, and it is not intended for use in humans or animals.

1. Nauck MA, Meier JJ. “Incretin hormones: Their role in health and disease.” Diabetes, Obesity and Metabolism, 2018. – https://pubmed.ncbi.nlm.nih.gov/29364588/
2. Frontiers in Endocrinology (2024) – “Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.” – https://www.frontiersin.org/journals/endocrinology
3. Campbell JE, Drucker DJ. “Pharmacology, physiology, and mechanisms of incretin hormone action.” Cell Metabolism, 2013. – https://pubmed.ncbi.nlm.nih.gov/23823483/